Introduction
An upper urinary tract stone is a very common disease, and the annual incidence is estimated to be 203.1 per 100,000 citizens in Japan 1 . Various conditions including distal renal tubular acidosis (type 1 RTA, dRTA) can induce stone formation in the kidney 2 . dRTA is characterized by an impairment of urine acidification due to the dysfunction of α-intercalated cells in the distal nephron 3 . Urinary stones formed in dRTA patients usually include a calcium phosphate component. Potassium citrate therapy is useful for the prevention of calcium stone formation in acidotic patients 4, 5 .
Acquired dRTA can be observed in patients with a variety of systemic and urinary tract diseases 2, 3 . dRTA is also caused by variations in genes functioning in α-intercalated cells, i.e., cytosolic carbonic anhydrase 2 (CA2) 6, 7 , ATP6V1B1 [8] [9] [10] encoding the B1 subunit of H + -ATPase, ATP6V0A4 encoding the A4 subunit of H + -ATPase, and SLC4A1/AE1/Band3 [11] [12] [13] encoding the Cl − /HCO3 − exchanger. The former three show autosomal recessive inheritance and the latter is autosomal dominant and autosomal recessive. Anion exchanger protein 1 (AE1) is a dimeric glycoprotein 14, 15 with 14 transmembrane domains 16 and it participates in the regulation of the intracellular pH by Cl -/HCO3 -exchange across the cell membrane. In the kidney, it is located at the basolateral membrane of α-intercalated cells and functions in the secretion of H + into the tubular lumen in cooperation with H + -ATPase and H + /K + -ATPase at the apical membrane 3, 17 .
Human SLC4A1/AE1/Band3 is a gene spanning 19.757 kb of genomic DNA situated on chromosome 17, q21-22. The gene consists of twenty exons and transcribes two kinds of mRNAs utilizing different promoters encoding the Cl-/HCO3-exchanger in erythrocytes (eAE1) and that expressed in α-intercalated cells in the kidney (kAE1). The promoter for human kAE1 is located in erythroid intron 3, and so the human kAE1 transcript lacks exons 1 through 3 of the eAE1 transcript 18 .
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We previously reported that in human erythroid intron 3 containing the promoter region of human kAE1, a single nucleotide polymorphism (SNP rs999716) showed a significantly higher minor allele A frequency in incomplete dRTA patients compared with those without dRTA 19 . The promoter region of the kAE1 gene with the minor allele A at rs999716, 39
basepairs downstream of the TATA box, showed reduced promoter activities compared with that of the major allele G, leading to the hypothesis that patients with the A allele at rs999716 may express less kAE1 mRNA and protein in the α-intercalated cells, developing incomplete dRTA.
Similarly to human kAE1 mRNA, mouse kAE1 mRNA lacks sequences of exons 1, 2, and 3, resulting in an N-terminal truncation of 79 amino acids compared with the mouse eAE1 protein [20] [21] [22] [23] . The internal initiation site of this truncated transcript was later identified in intron 3 of the mouse eAE1 gene 24 . Mouse kAE1 mRNA has an additional specific exon K1, which is located inside intron 3 and spliced to the 5-prime end of exon 4. A corresponding additional exon was also reported for human kAE1 mRNA 25 .
We have introduced single nucleotide variations in the downstream sequence of the TATA box in intron 3 of the murine AE1 gene to examine if these variations change the promoter activity for murine kAE1 mRNA transcription, as was seen in the human kAE1 gene.
Materials and Methods
Mouse kidney AE1 promoter region: Genomic DNA was extracted from the tail of the C57BL6 mouse using a kit (DNA Extractor® Kit, Wako, Osaka, Japan). Intron 3 of the mouse kAE1 gene containing a TATA box was amplified from 10 ng of the above genomic DNA by a pair of kAE1ProSen / kAE1ProAS primers ( Table 1 In conclusion, the engineered introduction of a G to A substitution into the 36 and 38 base pairs downstream of the TATA box in the murine kAE1
promoter region reduced the promoter activity, and may be a candidate method for establishing mouse models of incomplete dRTA and urolithiasis.
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